NEW PR
HUBBARD, Ohio--(BUSINESS WIRE)--NanoLogix Inc. (NNLX), an innovative biotechnology company in Northeastern Ohio announces that UNITAID, based in Geneva, Switzerland and hosted by the World Health Organization (WHO), on Friday published their Tuberculosis diagnostics technology and market landscape – 3rd edition. NanoLogix's sandwiched-membrane BNP rapid testing technology for tuberculosis is cited on pages 17 and 37 of the report. This is the second year that NanoLogix has been mentioned in the UNITAID annual report. The Company anticipates having their BNP technology included in TB studies in Africa and Australia in 2015. The BNP technology is patent pending in the United States, China, India and Brazil and received patents in Japan and Russia in 2014 and also notice of allowance of patent in the European Union in 2014, with the EU patent issuance expected in October 2014. NanoLogix's TB detection technology is well suited to the needs of medical personnel in remote areas, with rapid detection of TB bacteria in as little as 5 days available in a kit with extended shelf life and robust packaging.
Information about UNITAID , their press release, and their mission is available through the following link:
http://unitaid.org/en/rss-unitaid/1392-tuberc...rd-edition
A link to the annual report featuring NanoLogix technology on pages 17 and 37 is here:
http://unitaid.org/images/marketdynamics/publ...dition.pdf
The Ohio State University
NanoLogix is also pleased to announce that they have received a purchase order from The Ohio State University for provision of laboratory supplies to at least two departments on the Columbus campus. The purchase order term runs from 9/17/14 through 6/30/15. NanoLogix made their first delivery of product on 25 September. The Ohio State University joins the growing list of educational institutions ordering NanoLogix products. These include the University of Colorado -Boulder, Massachusetts Institute of Technology (MA), Worcester Polytechnic Institute (MA), and Cardiff University, (Wales, UK). The Company anticipates many more to come. In addition, NanoLogix has sold product to Abbott Labs, personal care companies, food processing companies, soil testing companies, the US EPA, and others who currently cannot be named due to contractual agreements. Mr. Hank Lewis, VP for Sales and Marketing and Michelle Durkin, Laboratory and New Products Director have interacted with multiple groups to achieve a number of these sales.
US Government Meeting
Mr Lewis and Bret Barnhizer, CEO, will be meeting with BARDA Program Representatives and ASPR Contracting Officers during BARDA Industry Day regarding Diagnostics and Medical Devices on October 17, 2014 in Washington, DC.
BARDA is:
U.S. Department of Health and Human Services (HHS)
Office of the Assistant Secretary for Preparedness and Response (ASPR)
Biomedical Advanced Research and Development Authority (BARDA)
Division of CBRN Countermeasures
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical, National Defense, and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.
Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity.
For more information visit: http://www.nanologix.com
This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
HUBBARD, Ohio--(BUSINESS WIRE)--NanoLogix Inc. (NNLX), an innovative biotechnology company in Northeastern Ohio announces that UNITAID, based in Geneva, Switzerland and hosted by the World Health Organization (WHO), on Friday published their Tuberculosis diagnostics technology and market landscape – 3rd edition. NanoLogix's sandwiched-membrane BNP rapid testing technology for tuberculosis is cited on pages 17 and 37 of the report. This is the second year that NanoLogix has been mentioned in the UNITAID annual report. The Company anticipates having their BNP technology included in TB studies in Africa and Australia in 2015. The BNP technology is patent pending in the United States, China, India and Brazil and received patents in Japan and Russia in 2014 and also notice of allowance of patent in the European Union in 2014, with the EU patent issuance expected in October 2014. NanoLogix's TB detection technology is well suited to the needs of medical personnel in remote areas, with rapid detection of TB bacteria in as little as 5 days available in a kit with extended shelf life and robust packaging.
Information about UNITAID , their press release, and their mission is available through the following link:
http://unitaid.org/en/rss-unitaid/1392-tuberc...rd-edition
A link to the annual report featuring NanoLogix technology on pages 17 and 37 is here:
http://unitaid.org/images/marketdynamics/publ...dition.pdf
The Ohio State University
NanoLogix is also pleased to announce that they have received a purchase order from The Ohio State University for provision of laboratory supplies to at least two departments on the Columbus campus. The purchase order term runs from 9/17/14 through 6/30/15. NanoLogix made their first delivery of product on 25 September. The Ohio State University joins the growing list of educational institutions ordering NanoLogix products. These include the University of Colorado -Boulder, Massachusetts Institute of Technology (MA), Worcester Polytechnic Institute (MA), and Cardiff University, (Wales, UK). The Company anticipates many more to come. In addition, NanoLogix has sold product to Abbott Labs, personal care companies, food processing companies, soil testing companies, the US EPA, and others who currently cannot be named due to contractual agreements. Mr. Hank Lewis, VP for Sales and Marketing and Michelle Durkin, Laboratory and New Products Director have interacted with multiple groups to achieve a number of these sales.
US Government Meeting
Mr Lewis and Bret Barnhizer, CEO, will be meeting with BARDA Program Representatives and ASPR Contracting Officers during BARDA Industry Day regarding Diagnostics and Medical Devices on October 17, 2014 in Washington, DC.
BARDA is:
U.S. Department of Health and Human Services (HHS)
Office of the Assistant Secretary for Preparedness and Response (ASPR)
Biomedical Advanced Research and Development Authority (BARDA)
Division of CBRN Countermeasures
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical, National Defense, and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.
Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity.
For more information visit: http://www.nanologix.com
This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
